AstraZeneca Stock News

The festive period is, for some, a time for taking stock of what's happened in the past year - for others, though, its a time to pick stocks for the year ahead. So it is, then, that it's the season for looking ahead.

The pharmaceutical company said its ceralasertib combination didn't meet the primary goal of a late-stage clinical trial for advanced lung cancer.

AstraZeneca said on Monday that a late‑stage trial testing Imfinzi in combination with ceralasertib failed to improve overall survival in patients with previously treated advanced non‑small cell lung cancer.

The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.

AstraZeneca targets $80bn revenue by FY2030, driven by oncology leadership and robust pipeline execution. AZN demonstrates double-digit revenue and EBITDA growth, trading at a discount to high-growth peers despite comparable operating leverage. DCF suggests limited upside under conservative assumptions, but peer-based multiples indicate substantial appreciation potential, supporting a GARP inve...

These top healthcare companies all have strong underlying businesses. Their low valuations can make them attractive for bargain hunters.

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Trump, according to sources familiar with the situation.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer, as determined by a Food and Drug Administration (FDA)-approved test. The approval follows Priority Review and Breakthroug...